Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a medical device company that focuses on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions using superficial radiotherapy (SRT and IG-SRT). The SRTS news page on Stock Titan aggregates company announcements, press releases and market updates so readers can follow how Sensus’ technology, reimbursement environment and commercial activities evolve over time.
Recent news highlights include recognition of Sensus Healthcare as a global pioneer in non-invasive treatments for skin cancer and keloids, updates on clinical evidence for its SRT systems, and developments in reimbursement policy. The company has reported that the Centers for Medicare & Medicaid Services established dedicated CPT codes specific to superficial radiotherapy for non-melanoma skin cancer, which Sensus describes as a pivotal moment for its platform and strategy. News items also cover growth in treatment volumes under its Fair Deal Agreement program and shipments of SRT systems to both U.S. and international customers.
Investors and healthcare professionals can use this news feed to track quarterly financial results, board and governance changes, conference participation, and recognition such as Sensus Healthcare’s inclusion in TIME’s America’s Growth Leaders of 2026 ranking. Clinical and scientific updates, including published studies on the use of SRT for keloids, provide additional context on how the company’s technology is being used in practice.
By reviewing the SRTS news stream regularly, readers can see how Sensus Healthcare communicates its progress in radiation oncology technology, reimbursement milestones, commercial expansion and clinical validation of its superficial radiotherapy solutions.
Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will participate in a panel discussion at the Fall Clinical Virtual Grand Rounds on June 30, 2020. The session is titled Directions in Dermatology and Their Impact on You: Patients, Practice and Pharma and focuses on superficial radiation therapy (SRT). This is part of a series aimed at providing continuing medical education (CME) to dermatologists during the pandemic. The event highlights Sensus’ commitment to supporting dermatology practices.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced that Dr. Jeffrey S. Fromowitz will discuss superficial radiation therapy at the Fall Clinical Virtual Grand Rounds today. This presentation will cover treatment for non-melanoma skin cancers and keloids, contributing to continuing medical education (CME) credits for participants. Dr. Fromowitz, a board-certified dermatologist, is affiliated with Dermatology of Boca and has advanced training in Mohs micrographic surgery. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions.
Sensus Healthcare (Nasdaq: SRTS) is hosting a program titled "Medical-Legal Issues in the Era of COVID-19" on June 18 at 3:00 p.m. ET. This event is part of a series aimed at discussing the role of superficial radiation therapy (SRT) amidst the pandemic. Hosted by CEO Joe Sardano and Dr. David Goldberg, the session addresses malpractice protections, employment issues, and telemedicine applications for SRT patients. The successful response to earlier events indicates strong interest in these discussions.
Sensus Healthcare (SRTS) reported Q1 2020 revenues of $1.7 million, down from $5.4 million in Q1 2019, attributed to COVID-19 impacts. The net loss widened to $3.6 million ($0.22 per share) from a loss of $2.1 million ($0.13 per share) a year prior. The company's installed base of SRT systems increased to 474, with four units shipped. Cash reserves rose slightly to $15.8 million. Management emphasized efforts to support customers during the pandemic and anticipates a potential increase in SRT adoption as reimbursement rates are expected to change in 2021.